Professor Hani Gabra
Consultant Medical Oncologist
BSc (Hons), MB ChB, MSc, PhD, MRCP, FRCPE, FRCP
"Spire Portsmouth is an excellent environment for patients with friendly, knowledgeable and efficient staff."
I have been a consultant medical oncologist specialising in gynaecological cancer (ovarian, uterine and cervical cancer), personalised cancer medicine, and cancer of unknown primary for 23 years. Initially 1998-2003 at the Western General Hospital in Edinburgh, at Imperial College London from 2003-21 and since June 2021 at Portsmouth Hospitals University NHS Trust. I am Portsmouth Hospitals University NHS Trust’s Lead Cancer Clinician.
I was Professor of Medical Oncology 2003-2020 at Imperial College London and since 2020 Professor Emeritus in Medical Oncology at Imperial College London. Since 2017 I have also had deep experience of early clinical drug development in a pharma and biotech setting, first as a Vice President in early clinical development at Astra Zeneca and then as Chief Medical Officer and Head of clinical development at BerGenBio, a clinical stage biotech company. I am also the founder of the biotech company Papyrus Therapeutics, based in the USA.
As well as being Professor Emeritus at Imperial College, I am also Adjunct Professor in Personalised Cancer Medicine at the University of Bergen, Norway and I hold a Visiting Professorship in Gynaecological Cancer at the Guanxi Medical University in Nanning, China.
Previously I held senior leadership roles at Imperial College including that of Director of the Ovarian Cancer Action Research Centre, Deputy Head of the Division of Cancer at Imperial College, Head of NHS Medical Oncology and Chief of Service for Gynaecological Cancer at Imperial College NHS Trust. I was a committee member of the Cancer Research UK’s CTAAC funding committee and the French INCa national research funding committee for five years.
Some of the principal treatments carried out by Professor Hani Gabra at Spire include:
Systemic treatment of cancer, targeted therapy and endocrine therapy
COVID-19 testing or antibody tests are not available as a standalone service at Spire Portsmouth Hospital.
B.Sc. (Hons) / University of Glasgow / 1984
Honours degree in Molecular Biology
MB, ChB / University of Glasgow / 1987
Degrees in Medicine and Surgery
MRCP / United Kingdom / 1990
Member of the Royal College of Physicians
MSc / University of Edinburgh / 1993
Ph.D / University of Edinburgh / 1997
Thesis: “Molecular and Cell Genetic Analysis of chromosome 11 in sporadic epithelial ovarian cancer”. Supervisor: Prof David Porteous
CCST (Med Oncol) / United Kingdom / 1998
General Medical Council Certificate of Completion of Specialist Training
FRCP (Edin) / Edinburgh / 2003
3 Fellow of the Royal College of Physicians of Edinburgh.
FRCP (Lond) / London / 2005
Fellow of the Royal College of Physicians of London
Portsmouth Hospitals University NHS Trust Lead Cancer Clinician
Consultant Medical Oncologist, Portsmouth Hospitals University NHS Trust
Professor Emeritus in Medical Oncology, Imperial College London
Honorary Consultant in Medical Oncology, Imperial College Healthcare NHS trust